MDT-AP-0746
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 27
- os_event
- true
- age_years
- 8
- sex
- F
- new_clusters
- C5
- umap1_2d
- 2.54550634
- umap2_2d
- 4.090414795
- umap1_3d
- 1.29265719
- umap2_3d
- 0.313034814
- umap3_3d
- -0.364143531
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.450
- INFLAMMATORY_RESPONSE+0.380
- COAGULATION+0.360
- PANCREAS_BETA_CELLS+0.340
- KRAS_SIGNALING_UP+0.330
- MYOGENESIS+0.320
- APICAL_SURFACE+0.300
- HEDGEHOG_SIGNALING+0.300
- ESTROGEN_RESPONSE_EARLY+0.280
- INTERFERON_ALPHA_RESPONSE+0.270
Top 10 suppressed
- MYC_TARGETS_V1-0.710
- E2F_TARGETS-0.650
- MYC_TARGETS_V2-0.630
- G2M_CHECKPOINT-0.600
- DNA_REPAIR-0.580
- UNFOLDED_PROTEIN_RESPONSE-0.550
- OXIDATIVE_PHOSPHORYLATION-0.530
- MITOTIC_SPINDLE-0.490
- PROTEIN_SECRETION-0.470
- MTORC1_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598336 | fetal | fetal | 0.955 |
| 2 | SRR1358826 | GTEX | — | 0.947 |
| 3 | MDT-AP-1215 | Med | Medulloblastoma | 0.939 |
| 4 | MNG1146 | — | — | 0.935 |
| 5 | SRR1366961 | GTEX | — | 0.935 |
| 6 | SRR1375203 | GTEX | — | 0.933 |
| 7 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.932 |
| 8 | SRR1315145 | GTEX | — | 0.932 |
| 9 | SRR1322456 | GTEX | — | 0.931 |
| 10 | SRR1317494 | GTEX | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.450 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |